Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo ...
3 Department of Epidemiology and Biostatistics, Academic Medical Centre, Amsterdam, the Netherlands Correspondence to: Dr C Y Ponsioen, Department of Gastroenterology and Hepatology, Hilversum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback